Loading clinical trials...
Loading clinical trials...
Endoscopic Submucosal Dissection Versus Local Laparoscopic Surgical Resection (Transanal Minimally Invasive Surgery [TAMIS] / Transanal Endoscopic Operation [TEO]) In Early Rectal Neoplasias. Multicentric and Randomized Clinical Trial
A multicenter non-inferiority randomized clinical trial to compare Endoscopic treatment (ESD) and Minimally Invasive Laparoscopic Local Surgical Treatment (TAMIS or TEO) for early rectal neoplastic lesions (adenoma \& T1CRC) Primary aim: To compare the long-term local recurrence rate (12 months after the procedure) Secondary aims: Compare en-bloq resection rate, R0 resection, time per procedure, short-term recurrence rate, safety (rate of complications), morbidity and cost-effectiveness analyses.
A multicenter non-inferiority randomized clinical trial is proposed to compare two types of treatment for early rectal neoplastic lesions. Study arms: 1. Endoscopic treatment: Endoscopic Submucosal Dissection (ESD) 2. Minimally invasive laparoscopic local surgical treatment: Transanal Minimally Invasive Surgery (TAMIS) or Transanal Endoscopic Operation (TEO). Aims: Primary aim: To compare the long-term local recurrence rate (12 months after the procedure) of rectal lesions after ESD vs Surgical treatment (TAMIS/TEO). Secondary aims: Both arms of the study are compared according to other efficacy-related variables (en-bloq resection rate, R0 resection, time per procedure, short-term recurrence rate \[6 months\]), safety (rate of complications), morbidity (comparing different specific indexes: Wexner index, EQ-5L-5D, etc) and cost-effectiveness analyses (QALY). Inclusion criteria: * Patients older than 18 y/o * Non-pedunculated rectal lesions (sessile 0-Is or flat 0-II) greater than 20 mm in diameter. * The edges of the lesion should be more than 3 cm from the external anal margin and up to 14 cm from it. * Circumferential involvement \<50% Exclusion criteria: * Patients who refuse to participate. * Diagnosis of inflammatory bowel disease with rectal involvement. * Pregnant. * Anorectal fibrosis due to previous anorectal surgery. * Lateral Spreading Lesions (LST classification) Granular Homogeneous type * Lesions greater than 50 mm when there is suspicion of advanced histology (Kudo Vi superficial pattern). * Rectal lesions of any size with high suspicion of deep submucosal invasion or locoregional lymph node involvement, either in the diagnostic colonoscopy (Kudo Vn crypt pattern, NICE 3 pattern, Sano IIIB pattern) or by complementary imaging tests (rectal EUS/Pelvic MRI) * Existence of synchronous colorectal lesions that require other surgical treatment in any case. N-size estimation: Assuming a global rate of long-term local recurrence in rectal lesions treated by TAMIS/TEO or ESD of 2.5% (using the data available in the medical literature), considering a non-inferiority limit of 10%, power of 80% (Beta error 0.2, alpha error 0.05) and assuming a loss of patients during the follow-up around 10%, 34 patients per group are required. Follow-up and Information collect: The follow-up will be of 1 year from the date of the intervention and the visits in which the information to be analyzed will be collected are adjusted to the usual clinical practice. The data would be registered using the on-line database system for medical research RedCap. Other information: The entire protocol of this study has been approved by de Ethical Committee on Clinical Research of the Puerta de Hierro University Hospital. The study counts with a Civil Responsibility Insurance policy.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Hospital de Sant Joan Despí Moisès Broggi
Barcelona, Barcelona, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Madrid, Spain
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, Spain
Start Date
April 1, 2019
Primary Completion Date
December 20, 2024
Completion Date
December 20, 2024
Last Updated
June 3, 2025
70
ACTUAL participants
ESD
PROCEDURE
TAMIS
PROCEDURE
TEO
PROCEDURE
Lead Sponsor
Dr. Alberto Herreros de Tejada Echanojáuregui
Collaborators
NCT06662786
NCT06663319
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05239741